ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2026
Implementation of a Pharmacogenomic Service in a Pediatric Community Hospital.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An often overlooked yet increasingly important factor in selecting appropriate medication therapy is a patient's genetic makeup. The primary goal of implementing a pharmacogenomics program is to reduce the risk of adverse drug reactions and decrease the risk of therapeutic failures. With recent technological advances, decreased cost of testing, and availability of pharmacogenomic guidance, pre-emptive pharmacogenomic testing has become more accessible and practical. Our institution's initiative to implement a clinical pharmacogenomics program reflects a broader commitment to advancing personalized medicine. We outline the processes and strategies employed to implement a pharmacogenomics service within a free-standing pediatric community hospital, with a pilot program focused on pediatric oncology patients. Various factors must be considered when implementing a pharmacogenomics program not limited to gene identification, laboratory selection, and technology integration. As the field continues to advance, our experience highlights the importance of adaptability, continuous learning, and a patient-centered approach to maximize the benefits of personalized medicine in pediatric care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.